Comparative Pharmacology
Head-to-head clinical analysis: ICLUSIG versus NINTEDANIB ESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ICLUSIG versus NINTEDANIB ESYLATE.
ICLUSIG vs NINTEDANIB ESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponatinib is a multi-targeted tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant form, and also inhibits VEGFR, PDGFR, FGFR, EPH receptors, and SRC family kinases.
Nintedanib esylate is a tyrosine kinase inhibitor that binds competitively to the ATP-binding pocket of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). This inhibition blocks downstream signaling pathways involved in angiogenesis and fibrosis.
45 mg orally once daily with or without food.
150 mg orally twice daily, 12 hours apart, taken with food.
None Documented
None Documented
Terminal elimination half-life is approximately 7.5 hours in healthy subjects, supporting twice-daily dosing.
Terminal elimination half-life is approximately 10 hours in patients with IPF; steady state reached within 7 days.
Primarily fecal (91%) as unchanged drug and metabolites; renal elimination accounts for less than 4% of the dose.
Biliary/fecal: >90% (unchanged and metabolites); Renal: <1%
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor